Key contacts

Klaus Schinkel

Klaus Schinkel
Director, Head of Germany

Regional office - Europe
Schumannstrasse 34b
60325, Frankfurt
Germany
Tel: +49 (0)69 78 8076 960
kschinkel@edisongroup.com

European listed companies

Biotie Therapies Corp Vivalis
NorDiag Thales
Orexo AB Science
Hutchison China MediTech EADS
Global Bioenergies Stallergenes
Core Laboratories Plaza Centers
Outotec Stentys
Albioma Erytech Pharma
Store Electronic Systems SinnerSchrader
Airbus Group Eurotunnel
See more

Companies with HQs in europe

Ixico IQE
Mondo TV Touchstone Innovations
Skyepharma BTG
Cineworld Topotarget
Acal Lok nStore Group
Randgold Resources Allergy Therapeutics
Safestore Holdings Ormonde Mining
Paion Wilex
Deinove Miton Income Opportunities Trust
TT electronics Advanced Computer Software Group
See more

Latest research

Paion

Positive data in high-risk patients

Update | Pharmaceutical & healthcare | 27/03/2017

Paion has taken an important step towards its goal of US approval for its ultra-fast-acting sedative, remimazolam with the announcement of positive top line results from a safety study in high risk colonoscopy patients. It is approaching another important milestone, with the confirmatory Phase III in bronchoscopy patients expected to complete recruitment soon; top line results are likely about two months later. Paion is on track to file for approval in both the US (in procedural sedation via partner…

Raven Russia

Emerging opportunities

Outlook | Property | 27/03/2017

Management’s outlook is cautiously optimistic and market conditions have improved since the start of 2016. Raven’s FY16 results show an IFRS profit of $7.7m or $55.4m on an EPRA basis. An opportunistic acquisition of three assets in St Petersburg announced since the year-end and expected to close in Q217 vindicates Raven’s strategy of strengthening the balance sheet in anticipation of the market changing. The defence of occupancy levels kept vacancies at 19% on average with leases…

Formycon

Surfing the next wave of biosimilars

Initiation | Pharmaceutical & healthcare | 27/03/2017

Formycon is a pure-play biosimilar company focused on third-wave biosimilars (those coming off patent after 2020), an overlooked opportunity for most biosimilar developers. The company has four compounds, two of which are partnered. FYB201 is a biosimilar of Lucentis for neovascular age-related macular degeneration (nAMD) undergoing a global Phase III study; the company is aiming for US and EU launch in 2020 and 2022, respectively, upon patent expiries. FYB203 is a proposed biosimilar of Eylea, also…

WYG

A good year, but not as good as anticipated

Update | Industrial Support Services | 24/03/2017

A slower end to FY17 for UK operations has lowered market guidance to c £9m EBIT for the year, c 12% below our previous estimate (but still c 23% above FY16) and we have adjusted our model accordingly. By the FY17 results announcement (on 6 June), we will have more visibility on run rates and order intake, and will naturally review estimates for FY18 and beyond at that time. Forward P/Es are now on single-digit multiples.

Transgene

Combination trials start, FY16 results

Update | Pharmaceutical & healthcare | 24/03/2017

Transgene has announced the initiation of two clinical trials of its main assets in combination with immune checkpoint inhibitors (ICIs). A Phase I trial of oncolytic virus Pexa-Vec in combination with Yervoy in solid tumours has started. Additionally, a Phase II study of the therapeutic vaccine TG4010 with Opdivo in second-line advanced lung cancer has started at UC Davis in collaboration with Bristol-Myers Squibb; initial results from both trials are expected later this year. Cash and equivalents…

About

Edison first opened its German office in Berlin in 2011. Now based in Frankfurt, we continue to provide research services to companies listed on mainland European stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports